title: On sepsis, troponin and vasopressin: the bitter truth.
abstract: One of the rationales for the use of vasopressin in septic shock has been its potential cardioprotective mechanisms. Lower heart rates, higher arterial pressures, and fewer norepinephrine doses during vasopressin therapy were hypothesized to protect the heart from myocardial ischemia. In a prospective sub-study of the VASST (Vasopressin in Septic Shock Trial) project, Mehta and colleagues specifically evaluated this hypothesis but failed to find lower cardiac biomarkers or fewer ischemic electrocardiogram changes in patients receiving vasopressin compared with subjects receiving norepinephrine alone. After recent evidence of a lacking survival benefit, the present study results further challenge the future role of vasopressin as a vasopressor in septic shock.
authors.forename: Ilse
authors.initials: I
authors.lastname: Gradwohl-Matis
authors.forename: Martin W
authors.initials: MW
authors.lastname: Dünser
mesh_terms: D005260:Female; D006801:Humans; D008297:Male; D017202:Myocardial Ischemia / Q000188:drug therapy*; D009638:Norepinephrine / Q000627:therapeutic use*; D012772:Shock, Septic / Q000188:drug therapy*; D014667:Vasopressins / Q000627:therapeutic use*
chemical_list: D014667:Vasopressins; D009638:Norepinephrine